<DOC>
	<DOC>NCT03070353</DOC>
	<brief_summary>A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI</brief_summary>
	<brief_title>Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury</brief_title>
	<detailed_description>A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40Â® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was &lt; 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Decompensated cirrhosis with acute kidney injury Ager over 18 years old Having chronic kidney disease, severe heart or lung disease, severe sepsis Pregnant Receiving nephrotoxic agents Having history of allergic to Dextran</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>AKI</keyword>
	<keyword>Albumin</keyword>
	<keyword>Dextran</keyword>
</DOC>